A5035683480- Inflammatory Bowel Disease
- Microscopic Colitis
- Liver Disease and Transplantation
- Diverticular Disease and Complications
- Acute Lymphoblastic Leukemia research
- Eosinophilic Esophagitis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Appendicitis Diagnosis and Management
- Metastasis and carcinoma case studies
- Gallbladder and Bile Duct Disorders
- Medical and Biological Ozone Research
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Gyrotron and Vacuum Electronics Research
- Gastrointestinal Tumor Research and Treatment
- Acne and Rosacea Treatments and Effects
- Autoimmune and Inflammatory Disorders
- Genetic factors in colorectal cancer
- Gastrointestinal motility and disorders
- Liver Diseases and Immunity
- Intraperitoneal and Appendiceal Malignancies
- Mycobacterium research and diagnosis
- Particle accelerators and beam dynamics
- Colorectal Cancer Screening and Detection
- Clostridium difficile and Clostridium perfringens research
- Diagnosis and treatment of tuberculosis
Hospital Universitario Puerta de Hierro Majadahonda
2015-2025
Hospital Universitario La Paz
2018
Abstract Background Colectomy is the primary treatment for dysplastic lesions in inflammatory bowel disease (IBD). Since development of advanced endoscopic techniques, management dysplasia evolving. Endoscopic submucosal resection (ESD) could be used selected cases at referral centres as an alternative to colectomy. However, feasibility and safety IBD remains limited. Main aim: To evaluate en-bloc rate need colectomy due ESD failure IBD. Secondary aims: assess complications ESD, local...
Abstract Background Tofacitinib, filgotinib, and upadacitinib, are Janus kinase inhibitors (iJAKs) approved for inflammatory bowel disease (IBD) treatment. Although no comparative studies exist, potential differences in efficacy safety attributed to vitro-demonstrated affinity of each molecule different JAK isoforms. JAK1 plays a crucial role modulating cytokine-mediated immune responses, such as IL-6 interferon, which involved inflammation skin homeostasis. Its inhibition can promote...
Early stages of Crohn's disease [CD] are predominantly inflammatory and early treatment could be useful to change the natural history CD. We aimed evaluate impact in our cohort CD patients.We retrospectively reviewed clinical records all patients at centre who have received immunomodulators. Time from diagnosis first CD-related major abdominal surgery or end follow-up was considered. Dates diagnosis, starting immunomodulators (thiopurines / anti-tumour necrosis factor [TNF]), when...
INTRODUCTION: The prevalence of penetrating complications in Crohn's disease (CD) increases progressively over time, but evidence on the medical treatment this setting is limited. aim study was to evaluate effectiveness biologic agents CD complicated with internal fistulizing disease. METHODS: Adult patients CD-related fistulae who received at least 1 agent for condition from prospectively maintained ENEIDA registry were included. Exclusion criteria involved those receiving biologics...
The impact of biologics on the risk postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack evidence more relevant for ustekinumab and vedolizumab.To evaluate PC.A retrospective study was performed 37 centres. Patients treated with within 12 weeks before surgery were considered "exposed". exposure 30-day PC infections assessed by logistic regression propensity score-matched analysis.A total 1535 surgeries 1370 patients. Of them, 711...
The possibility of developing idiopathic portal hypertension has been described with thiopurine treatment despite compromises the prognosis these patients, fact its true prevalence is unknown.A cross-sectional study was conducted in a cohort inflammatory bowel disease (IBD) patients followed at our unit, to determine diagnosis (IPH) and relationship treatment.At time analysis, 927/1,419 were under drugs (65%). A total 4 IBD type Crohn's probably related identified (incidence 4.3 cases per...
Chronic complications of acute appendicitis managed in a conservative manner are not frequent. We present case lower gastrointestinal hemorrhage young patient with previous without surgical intervention. The colonoscopy detected an appendicular bleeding which was surgically treated. anatomopathological diagnosis granulomatous appendicitis. clinical evolution the favorable recurrence. Appendicular can be unusual complication-however potentially severe-of treated surgically.
Background & aims Current therapeutic goals in ulcerative colitis (UC) include clinical and endoscopic remission, named mucosal healing (MH). Despite MH, a proportion of patients suffer relapse, which has been related to histological inflammation. We aimed identify histopathological features or index cut-off was associated with relapse (ER) UC MH. Methods Retrospective analysis who underwent surveillance colonoscopy showing complete MH (endoscopic Mayo subscore=0) random biopsies, at...
Malignant bile duct obstruction is a common entity in clinical practice and infrequently caused by non-biliopancreatic neoplasms. We report the case of male admitted with malignant biliary tract, showing after numerous studies that this was initial presentation stage IV adenocarcinoma lung. Pulmonary neoplasms have variable behaviors being often spread at time diagnosis, especially more aggressive subtypes. However, it uncommon its manifestation as obstructive jaundice when happens usually...
While the endoscopic remission is a well-established good prognostic factor, histological concept still to be defined, and therefore importance of this in evolution patients with ulcerative colitis (UC) uncertain. Getting may most ambitious stage. However, achieving it remission, probably makes difference. The Nancy index (NI) an activity for UC. It graduates from 0 4; 0) without relevant disease, (1) chronic inflammatory infiltrate acute infiltrate, (2) mild (3) moderate or severe (4)...
Faecal calprotectin (FC) is a biomarker of bowel inflammation widely spread in diagnosis and follow-up inflammatory disease (IBD). It classically estimated that 5% patients with axial spondyloarthritis (SpA) also have IBD; coexistence both conditions has definite impact clinical decisions. Proactive detection diseases should be advisable, though appropriate screening tools are still lacking. Our aim was to evaluate the usefulness FC for IBD diagnosed SpA without suggestive manifestations or...
Colonic lipomas are benign submucosal lesions which exceptionally may associate with colonic neoplasia or adenoma. LST-NG pseudo-depressed type over 2 cm commonly require en-bloc resection ESD other alternative techniques.
Abstract Background The risk of splanic vein thrombosis (SVT) -as defined as that involving the portal and/or its intrahepatic branches, mesenteric, splenic suprahepatic veïns is mainly observed, among others, in inflammatory abdominal conditions. Thromboembolic complications are frequent patients with bowel disease (IBD). However, there little information on prevalence, characteristics, factors and evolution SVT IBD. Our aims were to describe characteristics IBD, diagnostic explorations,...
Abstract Background Vedolizumab (VDZ) has shown efficacy in the treatment of inflammatory bowel disease (IBD). Available data show better outcomes naïve patients than AntiTNFa experienced patients, and current ECCO guidelines support first-line use VDZ since 2017. Nevertheless, reimbursement was initially approved Spain only failing to at least one agent (except contraindication) until January 2018 when, following a significative decrease costs VDZ, also patients. Our aim elucidate if our...
Abstract Background The prevalence of penetrating disease in Crohn’s (CD) increases progressively over time, and evidence on the medical treatment this complication is limited. aim study was to evaluate efficacy biologic agents CD complicated with internal fistulising disease. Methods A retrospective analysis all adult patients from ENEIDA registry (>68,000 patients) who received at least one agent -anti-TNF, ustekinumab or vedolizumab- for performed. Exclusion criteria comprised...
Abstract Background It has been suggested that biologic therapy may increase the risk of postoperative complications in inflammatory bowel disease (IBD), but evidence is scarce. Our aim was to evaluate whether treatment with anti-TNF agents, ustekinumab or vedolizumab after surgery. Methods IBD patients undergoing intra-abdominal surgery between 1st January 2009 and 31st December 2019 were retrospectively selected. Data collection included clinical characteristic IBD, biochemical parameters...